Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia
- Author
- O'BRIEN, Susan1 ; RIZZIERI, David A2 ; STAUDACHER, Karin10 ; BERGELAND, Trygve10 ; GILES, Francis J11 ; VEY, Norbert3 ; RAVANDI, Farhad4 ; KRUG, Utz O5 ; SEKERES, Mikkael A6 ; DENNIS, Mike7 ; VENDITTI, Adriano8 ; BERRY, Donald A9 ; FLEM JACOBSEN, Tove10
[1] Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, United States
[2] Cellular Therapy, Duke University Medical Center, Durham, NC, United States
[3] Groupe Francophone des Myelodysplasies (GFM), Bobigny, France
[4] Department of Leukemia, U.T. M.D. Anderson Cancer Center, Houston, TX, United States
[5] Department of Internal Medicine, Haematology/ Oncology, University of Münster, Münster, Germany
[6] Leukemia program, Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, United States
[7] Department of Haematology, Christie Hospital NHS Trust, Manchester, United Kingdom
[8] Department of Haematology, University Tor Vergata, Roma, Italy
[9] Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, United States
[10] Clinical, Clavis Pharma ASA, Oslo, Norway
[11] HRB Clinical Research Facilities, National University of Ireland Galway and Trinity College Dublin, Galway, Ireland - Source
British journal of haematology. 2012, Vol 158, Num 5, pp 581-588, 8 p ; ref : 1 p.1/2
- CODEN
- BJHEAL
- ISSN
- 0007-1048
- Scientific domain
- Medical oncology; Hematology
- Publisher
- Blackwell, Oxford
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- elacytarabine lipid esterification nucleoside analogue
- Keyword (fr)
- Activité biologique Analogue Anticancéreux Elacytarabine Estérification Homme Hématologie Leucémie aiguë myéloblastique Lipide Nucléoside Stade avancé Cancer Hémopathie maligne
- Keyword (en)
- Biological activity Analog Antineoplastic agent Elacytarabine Esterification Human Hematology Acute myelogenous leukemia Lipids Nucleoside Advanced stage Cancer Malignant hemopathy
- Keyword (es)
- Actividad biológica Análogo Anticanceroso Elacitarabina Esterificación Hombre Hematología Leucemia aguda mieloblástica Lípido Nucleósido Estadio avanzado Cáncer Hemopatía maligna
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B19 Hematologic and hematopoietic diseases / 002B19B Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
- Discipline
- Blood diseases
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 26275521
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1111/j.1365-2141.2012.09186.x 
https://dx.doi.org/10.1111/j.1365-2141.2012.09186.x
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2141.2012.09186.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:89:\"Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia\";s:9:\"\u0000*\u0000jtitle\";s:30:\"British journal of haematology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Br. j. haematol\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:3:\"158\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"581\";s:8:\"\u0000*\u0000epage\";s:3:\"588\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-1048\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"O'BRIEN\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Susan\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:17:\"RIZZIERI, David A\";i:1;s:17:\"STAUDACHER, Karin\";i:2;s:17:\"BERGELAND, Trygve\";i:3;s:16:\"GILES, Francis J\";i:4;s:12:\"VEY, Norbert\";i:5;s:15:\"RAVANDI, Farhad\";i:6;s:11:\"KRUG, Utz O\";i:7;s:18:\"SEKERES, Mikkael A\";i:8;s:12:\"DENNIS, Mike\";i:9;s:17:\"VENDITTI, Adriano\";i:10;s:15:\"BERRY, Donald A\";i:11;s:19:\"FLEM JACOBSEN, Tove\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJHEAL\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:89:\"Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2141.2012.09186.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:89:\"Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia\";s:9:\"\u0000*\u0000jtitle\";s:30:\"British journal of haematology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Br. j. haematol\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:3:\"158\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"581\";s:8:\"\u0000*\u0000epage\";s:3:\"588\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-1048\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"O'BRIEN\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Susan\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:17:\"RIZZIERI, David A\";i:1;s:17:\"STAUDACHER, Karin\";i:2;s:17:\"BERGELAND, Trygve\";i:3;s:16:\"GILES, Francis J\";i:4;s:12:\"VEY, Norbert\";i:5;s:15:\"RAVANDI, Farhad\";i:6;s:11:\"KRUG, Utz O\";i:7;s:18:\"SEKERES, Mikkael A\";i:8;s:12:\"DENNIS, Mike\";i:9;s:17:\"VENDITTI, Adriano\";i:10;s:15:\"BERRY, Donald A\";i:11;s:19:\"FLEM JACOBSEN, Tove\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJHEAL\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:89:\"Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2141.2012.09186.x\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2141.2012.09186.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:89:\"Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia\";s:9:\"\u0000*\u0000jtitle\";s:30:\"British journal of haematology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Br. j. haematol\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:3:\"158\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"581\";s:8:\"\u0000*\u0000epage\";s:3:\"588\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-1048\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"O'BRIEN\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Susan\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:17:\"RIZZIERI, David A\";i:1;s:17:\"STAUDACHER, Karin\";i:2;s:17:\"BERGELAND, Trygve\";i:3;s:16:\"GILES, Francis J\";i:4;s:12:\"VEY, Norbert\";i:5;s:15:\"RAVANDI, Farhad\";i:6;s:11:\"KRUG, Utz O\";i:7;s:18:\"SEKERES, Mikkael A\";i:8;s:12:\"DENNIS, Mike\";i:9;s:17:\"VENDITTI, Adriano\";i:10;s:15:\"BERRY, Donald A\";i:11;s:19:\"FLEM JACOBSEN, Tove\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJHEAL\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:89:\"Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2141.2012.09186.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:89:\"Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia\";s:9:\"\u0000*\u0000jtitle\";s:30:\"British journal of haematology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Br. j. haematol\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:3:\"158\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"581\";s:8:\"\u0000*\u0000epage\";s:3:\"588\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-1048\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"O'BRIEN\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Susan\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:17:\"RIZZIERI, David A\";i:1;s:17:\"STAUDACHER, Karin\";i:2;s:17:\"BERGELAND, Trygve\";i:3;s:16:\"GILES, Francis J\";i:4;s:12:\"VEY, Norbert\";i:5;s:15:\"RAVANDI, Farhad\";i:6;s:11:\"KRUG, Utz O\";i:7;s:18:\"SEKERES, Mikkael A\";i:8;s:12:\"DENNIS, Mike\";i:9;s:17:\"VENDITTI, Adriano\";i:10;s:15:\"BERRY, Donald A\";i:11;s:19:\"FLEM JACOBSEN, Tove\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJHEAL\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:89:\"Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2141.2012.09186.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:89:\"Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia\";s:9:\"\u0000*\u0000jtitle\";s:30:\"British journal of haematology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Br. j. haematol\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:3:\"158\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"581\";s:8:\"\u0000*\u0000epage\";s:3:\"588\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-1048\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"O'BRIEN\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Susan\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:17:\"RIZZIERI, David A\";i:1;s:17:\"STAUDACHER, Karin\";i:2;s:17:\"BERGELAND, Trygve\";i:3;s:16:\"GILES, Francis J\";i:4;s:12:\"VEY, Norbert\";i:5;s:15:\"RAVANDI, Farhad\";i:6;s:11:\"KRUG, Utz O\";i:7;s:18:\"SEKERES, Mikkael A\";i:8;s:12:\"DENNIS, Mike\";i:9;s:17:\"VENDITTI, Adriano\";i:10;s:15:\"BERRY, Donald A\";i:11;s:19:\"FLEM JACOBSEN, Tove\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJHEAL\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:89:\"Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
